|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 178.75 USD | -1.94% |
|
-3.87% | +94.44% |
| 06-12 | AstraZeneca says Truqap combination approved in US for prostate cancer | AN |
| 06-12 | AstraZeneca Says FDA Approves Truqap Combination for PTEN-Deficient Prostate Cancer | MT |
| Market Cap | 280B 242B 223B 209B 391B 26,639B 397B 2,634B 1,027B 12,966B 1,052B 1,029B 44,895B | P/E Ratio 2026 * |
22.8x | P/E Ratio 2027 * | 19.8x |
|---|---|---|---|---|---|
| Enterprise Value | 300B 259B 239B 223B 419B 28,502B 425B 2,818B 1,099B 13,873B 1,125B 1,101B 48,035B | EV / Sales 2026 * |
4.74x | EV / Sales 2027 * | 4.36x |
| Free-Float |
96.63% | Yield 2026 * |
1.85% | Yield 2027 * | 1.95% |
Last Transcript: AstraZeneca PLC
| 1 day | -1.94% | ||
| Current month | +92.68% | ||
| 6 months | +95.23% | ||
| Current year | +94.44% |
| Current year | 89.04 |  | 182.7 |
| 1 year | 68.62 | | 182.7 |
| 3 years | 60.47 | | 182.7 |
| 5 years | 52.65 | | 182.7 |
| 10 years | 25.55 | | 182.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 66 | 2012-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 52 | 2021-07-31 |
Pam Cheng
COO | Chief Operating Officer | 55 | 2015-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 1999-04-05 | |
Pascal Soriot
BRD | Director/Board Member | 66 | 2012-09-30 |
Philip Broadley
BRD | Director/Board Member | 65 | 2017-04-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.94% | -3.87% | - | - | 281B | |
| -2.41% | +0.14% | +39.53% | +154.43% | 1,035B | |
| +1.07% | +3.48% | +53.75% | +50.64% | 574B | |
| +1.32% | +0.22% | +18.35% | +65.35% | 397B | |
| +0.77% | 0.00% | +19.99% | +16.80% | 324B | |
| -1.42% | -1.44% | +45.50% | +8.37% | 298B | |
| +0.44% | +3.48% | +24.48% | +34.39% | 278B | |
| +1.66% | +1.20% | -44.67% | -47.49% | 193B | |
| +0.32% | +1.61% | +19.48% | +63.42% | 191B | |
| -0.22% | -2.76% | +12.08% | +61.30% | 156B | |
| Average | -0.39% | +0.97% | +20.94% | +45.24% | 383.02B | |
| Weighted average by Cap. | -0.88% | +1.15% | +29.85% | +71.05% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 63.32B 54.69B 50.4B 47.18B 88.41B 6,019B 89.78B 595B 232B 2,930B 238B 233B 10,144B | 67.16B 58B 53.45B 50.03B 93.76B 6,383B 95.21B 631B 246B 3,107B 252B 247B 10,758B |
| Net income | 12.43B 10.74B 9.89B 9.26B 17.35B 1,181B 17.62B 117B 45.54B 575B 46.65B 45.65B 1,991B | 14.09B 12.17B 11.21B 10.49B 19.67B 1,339B 19.97B 132B 51.61B 652B 52.86B 51.74B 2,256B |
| Net Debt | 19.6B 16.93B 15.6B 14.6B 27.36B 1,863B 27.78B 184B 71.8B 907B 73.54B 71.98B 3,139B | 12.67B 10.94B 10.08B 9.44B 17.69B 1,204B 17.96B 119B 46.42B 586B 47.54B 46.53B 2,029B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-12 | 178.75 $ | -1.94% | 2,394,262 |
| 26-06-11 | 182.28 $ | +1.86% | 1,749,433 |
| 26-06-10 | 178.96 $ | -2.44% | 2,129,693 |
| 26-06-09 | 183.43 $ | +1.04% | 1,963,806 |
| 26-06-08 | 181.55 $ | -2.37% | 2,040,150 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AZN Stock
- AZN Stock
Select your edition
All financial news and data tailored to specific country editions
